Management of the website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal.

Clinical Trial Details

Metabolic effects of oestrogen compounds in men with low testosterone

Print record Print record
Trial Information

Broad Health Condition Metabolic and Endocrine

Specific Health ConditionNormal metabolism and endocrine development and function

Trial FocusTreatment

Recruitment statusRecruiting

Anticipated date of first participant enrolment6/02/2008

Anticipated date of last participant enrolment6/02/2008

Phase of TrialPhase 4

Has the study received ethics approval?Further information iconApproved

Trial summary

We aim to investigate the effects of raloxifene (SERM) in hypogonadal men on the growth hormone system and metabolism.

Key inclusion criteria

Hypogonadism (prostate cancer patients on androgen deprivation therapy for at least 6 months)

Minimum age40 Years

Maximum age80 Years


Can Healthy volunteers participate?No

Key exclusion criteria

Androgen deprivation for less than 6 months, metastasis, cancer in other tissues than prostate, diabetes, kidney and liver disease, deep vein thrombosis
Contact details and further information

Sponsor Primary Sponsor Type: Hospital
Primary Sponsor Name: Department of Endocrinology, St Vincent's Hospital
Primary Sponsor Address: 390 Victoria St Darlinghurst, NSW 2010
Primary Sponsor Country: Australia

Trial IDACTRN12608000537358

Contact person for information and recruitment
Prof Ken Ho, MD, FRACP, Head of Dept of Endocrinology, St Vincent’s Hospital
Pituitary Research Unit Garvan Institute of Medical Research 384 Victoria Street Darlinghurst 2010 NSW
02 9295 8482
02 9295 8481
Further information